Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9056076 | APELLIS PHARMS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(2 years from now) | |
US8168584 | APELLIS PHARMS | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Apr, 2027
(2 years from now) |
Syfovre is owned by Apellis Pharms.
Syfovre contains Pegcetacoplan.
Syfovre has a total of 10 drug patents out of which 0 drug patents have expired.
Syfovre was authorised for market use on 17 February, 2023.
Syfovre is available in solution;intravitreal dosage forms.
Syfovre can be used as treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan, treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan and also administering an anti-vegf agent, treatment of geographic atrophy secondary to age-related macular degeneration by administering complement inhibitor pegcetacoplan.
Drug patent challenges can be filed against Syfovre from 14 May, 2025.
The generics of Syfovre are possible to be released after 15 November, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 22, 2026 |
New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...
Dosage: SOLUTION;INTRAVITREAL